A device smaller than a grain of dust is emerging as a surprisingly powerful candidate to reshape how quantum computers are ...

First Patient Dosed with Intranasal Foralumab in Randomized, Placebo-Controlled Phase 2 TrialBuilds on Recent Evidence of Persistent Neuroinflammation in Alzheimer’s Patients Treated with Anti-Amyloid ...

The hair follicle is a highly dynamic mini-organ that undergoes cyclic phases of growth, regression, and rest. The anagen ...

Impressively, the unit registered the lowest frequency loss of any chip to date. Specifically, the engineers noted that the new chip was 15x more stable and 100x more efficient in terms of microwave ...

TAMPA, Fla. and LONDON, Dec. 30, 2025 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing antibody drug conjugates (ADCs) with novel payloads today ...

Biohaven Ltd. (NYSE: BHVN) ("Biohaven"), a global clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization ...

OV350 showed a good safety profile, supporting the advancement of the Company’s KCC2 portfolio, including the first oral direct activator, OV4071There were no treatment-related laboratory findings, no ...

Although the results of this study do not support the efficacy of BHV-7000 in a broad population of depressed patients, we ...

Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing antibody drug conjugates (ADCs) with novel payloads, today ...

TAMPA, Fla. and LONDON, Dec. 23, 2025 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology ...

Learn more about whether Legend Biotech Corporation or Zymeworks Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

-- First Patient Expected to be Dosed Next Week with Intranasal Foralumab -- PET Scan Shows Presence of Untreated Neuroinflammation in Alzheimer's Patient on Leqembi (R) (Lecanemab) Anti-Amyloid ...